Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517115-70-00

Acronym

NL79578.100.21

Enrollment

Registered

2024-08-15

Start date

2022-05-04

Completion date

Unknown

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent foramen ovale or atrial septum defect

Brief summary

This study will capture the following hemostatic endpoints: • Coagulation activation (e.g. prothrombin fragment 1+2, thrombin antithrombin III complex) • Platelet activation (e.g. P-selectin, CD40 ligand) • Von Willebrand Factor Antigen (VWF Ag) • Beta-thrombglobulin (beta-TG) • Plasminogen activator inhibitor-1 (PAI-1) • D-dimer • Thrombin Generation Test • Anti Xa activity

Interventions

DRUGXarelto 20 mg film-coated tablets

DRUGPlavix 75 mg film-coated tablets

DRUGACETYLSALICYLIC ACID

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
This study will capture the following hemostatic endpoints: • Coagulation activation (e.g. prothrombin fragment 1+2, thrombin antithrombin III complex) • Platelet activation (e.g. P-selectin, CD40 ligand) • Von Willebrand Factor Antigen (VWF Ag) • Beta-thrombglobulin (beta-TG) • Plasminogen activator inhibitor-1 (PAI-1) • D-dimer • Thrombin Generation Test • Anti Xa activity	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026